Screener
Haemonetics HAE Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | June 27, 2026 | March 28, 2026 |
|---|---|---|
| Other current liabilities | 163,796 | 158,337 |
| Total current liabilities | 263,235 | 282,599 |
| Long-term debt | 1,169,202 | 1,219,565 |
| Deferred tax liability | 38,691 | 38,048 |
| Other long-term liabilities | 57,171 | 59,393 |
| Stockholders’ equity: | ||
| Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 45,471,313 shares as of June 27, 2026 and 45,252,667 shares as of March 28, 2026 | 455 | 453 |
| Additional paid-in capital | 566,759 | 554,137 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's deferred tax assets?
- Haemonetics (HAE) reported deferred tax assets of $38.69M in Q2 2026.
- How has Haemonetics's deferred tax assets changed year-over-year?
- Haemonetics's deferred tax assets decreased by 35.0% year-over-year, from $59.49M to $38.69M.
- What is the long-term trend for Haemonetics's deferred tax assets?
- Over 5 years (2021 to 2026), Haemonetics's deferred tax assets has grown at a -2.8% compound annual growth rate (CAGR), from $43.83M to $38.05M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Haemonetics's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude